Home World News EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib World News EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib By Ogkologos - May 22, 2026 341 0 Facebook Twitter Google+ Pinterest WhatsApp Palbociclib Viatris is a generic of Ibrance which has been authorised in the EU since 2016 Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Combination Therapy for Metastatic Prostate Cancer Helps Some Men Live Longer March 11, 2025 Adding Pembrolizumab to Platinum-Based Chemotherapy Improves Survival in Patients with Previously... June 23, 2023 Optimistic targets aren’t enough – this is what we need to... July 19, 2023 Foodie Friday: Watermelon Fruit Pizza September 3, 2021 Load more HOT NEWS ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... Study Finds Most Women Who ‘Go Flat’ After Mastectomy Are Happy... What to Know About Biomarker Testing for Lung Cancer: An Expert... Trend in Survival Benefit with a Combination of Spartalizumab Plus Dabrafenib...
